Company Directory / research
PrivateFor profitresearchCharleroi, Belgium
AbolerIS Pharma
AbolerIS Pharma develops immuno-modulators as treatments for transplant rejection, graft-versus-host disease, and auto-immune diseases.
- Founded
- 2019 7 years ago
- Staff
- 11-50 band, as listed
- Followers
- - on LinkedIn
- Funding
- $30M as listed, currency not stated
Set against six million companies
Size
11-50 people: larger than 33% of companies with a size listed
Age
7 years old.
Reach
Website ranked #12,817,090 in the world for traffic, about 79 visits a month.
What it does
Biotechnology
Funding, as listed
$30M currency not stated
- Rounds2
- LatestSeries a, Sept 2023
- Investors8, 4 leading
What the source datasets report. We have not watched these rounds ourselves.
Every detail we hold
Everything the source datasets list about AbolerIS Pharma, field by field. Contact details are held but never shown.
The company
- Name
- AbolerIS Pharma
- Type
- For profit
- Status
- Private
- Founded
- 2019
- Founders
- Carole Guillonneau, F.-Xavier HUBERT, Ignacio Anegon
- Industry
- research
- Categories
- Biotechnology
Where
- City
- Charleroi
- Country
- Belgium
- Markets
- European Union (EU), Europe, Middle East, and Africa (EMEA)
Size and reach
- Staff band
- 11-50
- Web traffic rank
- #12,817,090
- Monthly web visits
- 79
Funding, as listed
- Total
- 29,800,000 (currency not stated)
- Rounds
- 2
- Latest round
- Series a
- Latest round date
- Sept 2023
- Investors
- 8
- Lead investors
- 4
- Listing status
- private
About this record
- Sources
- Crunchbase
- Last imported
- Sept 2026
Growth, as the source summarises it
AbolerIS Pharma may be growing as it has successfully secured a significant amount of funding, specifically €27.3 million in Series A financing. This influx of capital is indicative of investor confidence and provides the financial resources necessary for further research and development, which is critical in the biotechnology industry. The ability to raise such a substantial amount suggests that AbolerIS Pharma is in a position to advance its pipeline of immuno-modulators and potentially expand its operations or workforce to support its growth trajectory.
Summaries written by the source dataset, not by us, and not checked.
Companies like it
research in Belgium.
From the company datasets we hold (Crunchbase, LinkedIn and Apollo listings), as listed there; 36,920 companies in Belgium and 5,926,251 in all. We hold no contact details for public display. Correct this, or ask for it to be removed.